OncoMatch

OncoMatch/Clinical Trials/NCT04929223

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Is NCT04929223 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for metastatic colorectal cancer.

Phase 1RecruitingHoffmann-La RocheNCT04929223Data as of May 2026

Treatment: Inavolisib · Bevacizumab · Cetuximab · Atezolizumab · Tiragolumab · SY-5609 · Divarasib · FOLFOX · FOLFIRIThis open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: systemic therapy for metastatic disease — metastatic

Prior therapies for metastatic disease

Cannot have received: systemic anti-cancer treatment

Any systemic anti-cancer treatment within 2 weeks or 5 half-lives (whichever is shorter) prior to start of study treatment

Cannot have received: investigational therapy

Treatment with investigational therapy within 28 days prior to initiation of study treatment

Lab requirements

Blood counts

Adequate hematologic function within 14 days prior to initiation of study treatment

Kidney function

Adequate organ function within 14 days prior to initiation of study treatment

Liver function

Adequate organ function within 14 days prior to initiation of study treatment

Adequate hematologic and organ function within 14 days prior to initiation of study treatment

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • UAB Comprehensive Cancer Center · Birmingham, Alabama
  • Mayo Clinic Arizona · Phoenix, Arizona
  • City of Hope Comprehensive Cancer Center · Duarte, California
  • cCare · Encinitas, California
  • USC Norris Cancer Center · Los Angeles, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify